Cardiac remodeling occurs frequently in chronic kidney disease patients and affects quality
of life and survival. Current treatment options are highly inadequate. As kidney function …

Cardiac hypertrophy is a common feature in patients with CKD. Recent studies revealed that
two phosphate regulators, fibroblast growth factor-23 and α-Klotho, are highly involved in the …

Myocardial fibrosis is often associated with cardiac hypertrophy; indeed, fibrosis is one of the
most critical factors affecting prognosis. We aimed to identify the molecules involved in …

Rationale & Objective Studies using a single measurement of fibroblast growth factor 23
(FGF-23) suggest that elevated FGF-23 levels are associated with increased risk for …

Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney
disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression …

Objective: To explore the relationship between the polymorphism of angiotensinogen gene
(AGT) M235T and susceptibility to hypertrophic cardiomyopathy (HCM) in Asian population …

The mechanism of action of fibroblast growth factor‐23 (FGF23) is becoming increasingly
clearer as a result of studies that have defined its structure and pleiotropic effects …

Background Experimental studies have shown fibroblast growth factor 23 (FGF23)-mediated
upregulation of the distal tubule sodium/chloride (Na+ Cl−) co-transporter leading to …

The physiological mineralisation of skeletal tissues, as well as the pathological
mineralisation of soft tissues involves a fine balance between regulators that either promote …

Основным морфологическим субстратом структурного поражения миокарда является
фиброз. Процессы фиброзирования определенным образом ассоциируются с …